- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nuvalent Inc (NUVL)
Nuvalent Inc stock price live, this page displays NASDAQ NUVL stock exchange data. View the NUVL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nuvalent Inc real time stock price chart below.
What Is the Nuvalent Inc Stock Price Today?
The Nuvalent Inc stock price today is 90.95.
What Is the Stock Symbol for Nuvalent Inc?
The stock symbol for Nuvalent Inc is "NUVL."
What Stock Exchange Does Nuvalent Inc Trade On?
Nuvalent Inc is listed and trades on the NASDAQ stock exchange.
Is Nuvalent Inc a Good Stock to Buy?
Determining whether Nuvalent Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NUVL quote. (ISIN: US6707031075)
What Is the Nuvalent Inc Stock Price Today?
The Nuvalent Inc stock price today is 90.95.
What Is the Stock Symbol for Nuvalent Inc?
The stock symbol for Nuvalent Inc is "NUVL."
What Stock Exchange Does Nuvalent Inc Trade On?
Nuvalent Inc is listed and trades on the NASDAQ stock exchange.
Is Nuvalent Inc a Good Stock to Buy?
Determining whether Nuvalent Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NUVL quote. (ISIN: US6707031075)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
90.40
94.08
52 wk Range
71.13
113.02
NUVL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
90.4094.08
52 wk Range
71.13113.02
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NUVL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
143.62
Upside
+57.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
8 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
20 Buy
0 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 143.62
(+57.91% Upside)
Nuvalent Inc SWOT Analysis
Pipeline Progress | Explore Nuvalent's advancing oncology pipeline, with zidesamtinib and neladalkib showing promise in ROS1 and ALK-positive NSCLC clinical trials |
Market Potential | Delve into Nuvalent's strategy to capture both treatment-experienced and first-line markets, potentially positioning it as a leader in targeted therapies |
Financial Outlook | Analysts maintain a positive stance with a $100 price target, despite current unprofitability. EPS projections for FY2025 stand at -$5.07 |
Competitive Edge | Learn how Nuvalent's focus on improved safety profiles and efficacy could differentiate its therapies in the crowded oncology landscape |
Earnings
Latest Release
May 07, 2026
EPS / Forecast
-1,39 / -1,35
Revenue / Forecast
-- / --
Compare NUVL to Peers and Sector
Metrics to compare | NUVL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNUVLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.0x | −4.3x | −0.5x | |
PEG Ratio | 0.43 | 0.02 | 0.00 | |
Price/Book | 6.1x | 3.1x | 2.6x | |
Price / LTM Sales | - | 108.2x | 3.0x | |
Upside (Analyst Target) | 56.1% | 119.6% | 58.7% | |
Fair Value Upside | Unlock | 12.8% | 10.3% | Unlock |
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Nuvalent (NUVL) Stock Price Today?
The Nuvalent stock price today is 90,95 USD.
What Stock Exchange Does Nuvalent Trade On?
Nuvalent is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Nuvalent?
The stock symbol for Nuvalent is "NUVL."
What Is the Nuvalent Market Cap?
As of today, Nuvalent market cap is 7,18B USD.
What Is Nuvalent's Earnings Per Share (TTM)?
The Nuvalent EPS (TTM) is -6,05.
When Is the Next Nuvalent Earnings Date?
Nuvalent will release its next earnings report on Aug 06, 2026.
From a Technical Analysis Perspective, Is NUVL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Nuvalent Stock Split?
Nuvalent has split 0 times.
How Many Employees Does Nuvalent Have?
Nuvalent has 234 employees.
What is the current trading status of Nuvalent (NUVL)?
As of Jun 07, 2026, Nuvalent (NUVL) is trading at a price of 90,95 USD, with a previous close of 94,02 USD. The stock has fluctuated within a day range of 90,40 USD to 94,08 USD, while its 52-week range spans from 71,13 USD to 113,02 USD.
What Is Nuvalent (NUVL) Price Target According to Analysts?
The average 12-month price target for Nuvalent is 143,62 USD, with a high estimate of 172 USD and a low estimate of 116 USD. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +57,91% Upside potential.
What Is the NUVL Premarket Price?
NUVL's last pre-market stock price is 94,24 USD. The pre-market share volume is 1 480,00, and the stock has decreased by 0,22, or 0,23%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.